PIRCHE® is a new technology for estimating risk of immune responses after transplantation. It is the first HLA matching algorithm taking account the indirect pathway of allo-recognition.
In solid organ transplantation (SOT), the algorithm considers peptide mismatches from the donor presented on HLA class II molecules of the patient to CD4+ T cells.
In mismatched HLA proteins certain amino acid positions differ between patient and donor. In antigen presenting cells of the patient, these proteins are processed via protease and other processes into smaller peptides.
In stem cell transplantation (SCT), the PIRCHE algorithm considers mismatched HLA protein fragments of the patient, that can be detected by donor CD8+ (presented by shared HLA class I) and CD4+ (presented by shared HLA class II) T cells.
HLA antigens mismatched between patient and donor vary in certain amino acid positions. In antigen presenting cells, these are processed via protease and other processes into smaller peptides.
In the oncological setting, PIRCHE provides analyses and simulations around the immunocompatiblity between introduced HLA and the patient’s immune system. The results of these analyses will guide the selection of antigens to induce to cover the majority of the patient population.
In the clinical setting, PIRCHE will provide the tools to select a specific antigen line that induces the strongest immune reaction so the desired medication performs best.